

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山医药集团股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 00874)

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTORS

This announcement is made by the board (the “**Board**”) of directors (the “**Director(s)**”) of Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

In accordance with the Company’s articles of association, the Company Law of the People’s Republic of China and other applicable laws and regulations, the Board proposes to appoint Mr. Cheng Hongjin (“**Mr. Cheng**”) and Mr. Tang Heping (“**Mr. Tang**”) as executive directors of the 9th session of the Board of the Company.

BIOGRAPHICAL DETAILS OF MR. CHENG AND MR. TANG

Mr. Cheng, aged 55, is a member of the Communist Party of China. He holds a postgraduate degree, a master of Business Administration (MBA), and professional qualifications as an engineer and a senior labor relations coordinator. Mr. Cheng began his career in July 1993, and has successively served as deputy leader of the preparatory group, deputy chairman of the labor union, director of the labor union office, general manager of the operations department, and general manager of the strategic planning department of Guangzhou Industrial Investment Holdings Group (廣州工業投資控股集團有限公司); director of the Guangzhou Industrial Control Industry Research and Integration Center (廣州工控產業研究整合中心); director of Guangdong Southern Soda Ash Co., Ltd. (廣東南方城業股份有限公司); full-time external director of Guangzhou Public Transport Group Co., Ltd. (廣州市公共交通集團有限公司), Guangzhou City Construction Investment Group Co., Ltd. (廣州市城市建設投資集團有限公司), and Guangzhou Construction Group Co., Ltd (廣州市建築集團有限公司). Currently, Mr. Cheng serves as a member of the party committee and deputy general manager of Guangzhou Pharmaceutical Holdings Limited (“**GPHL**”). Mr. Cheng has extensive experience in corporate strategic planning, industrial integration and conglomerate governance.

Mr. Tang, aged 53, is a member of the Communist Party of China. He holds a postgraduate degree, a master of Management. He is certified as a senior accountant and a Certified Public Accountant. Mr. Tang commenced his professional career in July 1992, and has successively served as audit manager, director of financial settlement center, and accounting manager of Shenzhen Gas Corporation Ltd. (深圳市燃氣集團股份有限公司); deputy director and subsequently director of the finance department, chief financial officer of Guangzhou Friendship Group Co., Ltd. (廣州友誼集團股份有限公司); chairperson of the supervisory committee of Guangzhou Department Store Enterprise Group Co., Ltd., currently known as Guangzhou Lingnan Business and Travel Investment Group Co., Ltd. (廣州百貨企業集團有限公司, 現名為廣州領南商旅投資集團有限公司) and Guangzhou Pearl River Enterprises Group Co., Ltd. (廣州珠江實業集團有限公司). Currently, Mr. Tang holds the positions of chief accountant and party committee member of GPHL, party committee member of the Company and chairperson of the supervisory committee of Guangzhou Pearl River Piano Group Co., Ltd. (廣州珠江鋼琴集團股份有限公司). Mr. Tang has extensive experience in corporate audit governance, supervisory committee oversight, and financial accounting management.

TERM OF THEIR OFFICE

Upon approval of the appointments of Mr. Cheng and Mr. Tang by the shareholders of the Company at a general meeting, the Company will enter into service contracts with them for terms commencing from the date of such approval and ending upon the expiry of the tenure of the 9th session of the Board of the Company. Pursuant to the articles of association of the Company, Mr. Cheng and Mr. Tang are eligible for re-election upon the expiry of their respective terms of office.

REMUNERATION

Since Mr. Cheng and Mr. Tang, both being members of the senior management of GPHL (the controlling shareholder of the Company), receive their respective emoluments from GPHL, if elected, each of them will receive no emoluments from the Company for the year 2025.

As at the date of this announcement, save as disclosed, Mr. Cheng and Mr. Tang:

- (i) have not held any directorships in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas;
- (ii) have no other major appointments or professional qualifications;
- (iii) have no interest, nor are they are deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong);
- (iv) have no relationship with any other Directors, supervisors, senior management members, or substantial or controlling shareholders of the Company; and

- (v) There is no other matter in relation to the proposed appointment of Mr. Cheng and Mr. Tang that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited, nor is there any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

GENERAL

The proposed appointment of Mr. Cheng and Mr. Tang as executive directors of the Company is subject to the approval of the shareholders of the Company by way of ordinary resolutions at a general meeting. A circular containing, among other things, details of the above proposed appointments and a notice of the general meeting will be despatched to the shareholders as soon as practicable.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 29 April 2025

As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Mr. Yang Jun, Ms. Cheng Ning and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.